During the recent session, Skye Bioscience Inc (NASDAQ:SKYE)’s traded shares were 1.29 million, with the beta value of the company hitting 1.81. At the last check today, the stock’s price was $3.02, reflecting an intraday loss of -44.99% or -$2.47. The 52-week high for the SKYE share is $19.41, that puts it down -542.72 from that peak though still a striking 52.32% gain since the share price plummeted to a 52-week low of $1.44. The company’s market capitalization is $91.63M, and the average intraday trading volume over the past 10 days was 0.17 million shares, and the average trade volume was 239.49K shares over the past three months.
Skye Bioscience Inc (SKYE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SKYE has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.25.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Skye Bioscience Inc (NASDAQ:SKYE) trade information
Skye Bioscience Inc (SKYE) registered a -44.99% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -44.99% in intraday trading to $3.02, hitting a weekly high. The stock’s 5-day price performance is -49.67%, and it has moved by -44.99% in 30 days. Based on these gigs, the overall price performance for the year is -5.63%. The short interest in Skye Bioscience Inc (NASDAQ:SKYE) is 1.15 million shares and it means that shorts have 6.16 day(s) to cover.
The consensus price target of analysts on Wall Street is $20, which implies an increase of 84.9% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15 and $21 respectively. As a result, SKYE is trading at a discount of -595.36% off the target high and -396.69% off the low.
Skye Bioscience Inc (SKYE) estimates and forecasts
Statistics show that Skye Bioscience Inc has outperformed its competitors in share price, compared to the industry in which it operates. Skye Bioscience Inc (SKYE) shares have gone down -76.59% during the last six months, with a year-to-date growth rate more than the industry average at 80.26% against 17.30.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.94%. While earnings are projected to return 81.19% in 2024.
SKYE Dividends
Skye Bioscience Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Skye Bioscience Inc (NASDAQ:SKYE)’s Major holders
Skye Bioscience Inc insiders own 2.08% of total outstanding shares while institutional holders control 83.63%, with the float percentage being 85.41%.
